ALB and hepatocellular carcinoma: Following Cox regression analysis, it was observed that age (increasing years; HR = 1.08; 95% CI 1.04-1.13), male sex (HR = 2.76; 95% CI 1.28–5.96), lower baseline albumin levels (HR = 3.94 95%; CI 1.81–8.58), genotype 3 (HR = 5.05; 95% CI 1.75–14.57) and serum anti-HBc positivity (HR = 1.99; 95% CI 1.01–3.95) were factors independently associated with de novo HCC occurrence after successful DAA treatment (Table 3).